Innovative Journal of Medical Sciences <div id="myCarousel" data-ride="carousel"> <div> <div style="text-align: justify;"><strong>Innovative Journal of Medical Sciences</strong><strong> (IJMS) </strong>is an international Referred and Peer Reviewed Online Journal with E-ISSN: 2581-4346 published by B.R. Nahata Smriti Sansthan for the enhancement of Medical Sciences subject areas. The journal’s full text is available online at <a href=""></a> . The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles. The Journal has been designed to cover all the fields of research, which has any correlation and impact on Pharmaceutical and medical science. IJMS aims for a quick publication of research articles post review by the Editorial Board. <strong>IJMS free submission provides platform for the new researchers to get there researches published with rapid review.</strong> The members of the Editorial Board of IJMS are of international stature coming across the globe, many of whom are well known eminent academicians and researchers which allows the complete coverage of the scope of the journal. IJMS accepts new technologies, or research or research methods with applicability to pharmacy practice in fields such as pharmaceutical care, medication therapy management, Pharmaceutical Technology, Pharmacognosy, Natural Product Research, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest , Medical science ,APHE , Organ system, psychosocial aspects of medication use, pharmacoeconomics, pharmacotherapy, pharmacoepidemiology, pharmacy law, pharmacy management, public health, and health care financing.</div> </div> </div> <div style="text-align: justify;"> <p style="text-align: justify;"> </p> <p style="text-align: justify;"><strong><span style="text-decoration: underline;">SUBJECT CATEGORY </span></strong></p> <p style="text-align: justify;"><strong>Papers reporting original research and innovative applications from all parts of the world are welcome.</strong></p> <p style="text-align: justify;"><strong>Subject areas suitable for publication include, but are not limited to the following fields:</strong></p> <ul style="text-align: justify;"> <li>Pharmaceutical care,</li> <li>Medication therapy management,</li> <li>Pharmaceutical technology,</li> <li>Pharmacognosy,</li> <li>Natural product research,</li> <li>Pharmaceutics,</li> <li>Novel drug delivery,</li> <li>Biopharmaceutics,</li> <li>Pharmacokinetics,</li> <li>Pharmaceutical/medicinal chemistry,</li> <li>Computational chemistry and molecular drug design,</li> <li>Pharmacology,</li> <li>Pharmaceutical analysis,</li> <li>Pharmacy practice,</li> <li>Clinical and hospital pharmacy,</li> <li>Cell biology,</li> <li>Genomics and proteomics,</li> <li>Pharmacogenomics,</li> <li>Bioinformatics and biotechnology of pharmaceutical interest,</li> <li>Medical science,</li> <li>APHE</li> <li>Organ system,</li> <li>Psychosocial aspects of medication use,</li> <li>Pharmacoeconomics,</li> <li>Pharmacotherapy,</li> <li>Pharmacoepidemiology,</li> <li>Pharmacy law,</li> <li>Pharmacy management,</li> <li>Public health and health care financing.</li> <li>Anatomical pathology</li> <li>Cytology</li> <li>Immunology</li> <li>Clinical biochemistry</li> <li>Microbiology</li> <li>Blood transfusion</li> <li>Haematology</li> <li>Virology</li> <li>Genetics and Molecular pathology</li> <li>Cardiology (Heart Care)</li> <li>Oncology (Cancer Care)</li> <li>Neurology</li> <li>Urology</li> <li>Surgical Gastroenterology</li> <li>Medical Gastroenterology</li> <li>Obstetrics and Gynecology</li> <li>Bone Marrow Transplant</li> <li>Orthopedics &amp; Joint Replacement</li> <li>Pulmonology (Lung Diseases)</li> <li>Bariatric/Weight Loss Surgery</li> <li>Robotic Surgery</li> <li>Liver Transplant</li> <li>Kidney Transplant</li> <li>Reproductive Medicine (IVF)</li> <li>Aerospace Medicine</li> <li>Anesthesia</li> <li>Bariatric Surgery</li> <li>Cardiology - Interventional</li> <li>Cardiology - Non Interventional</li> <li>Cardiothoracic And Vascular Surgery</li> <li>Centre For Spinal Diseases</li> <li>Clinical Haematology And BMT</li> <li>Corneal Transplant</li> <li>Critical Care Medicine</li> <li>Dermatology And Cosmetology</li> <li>Ear Nose Throat Head And Neck Surgery</li> <li>Emergency Medicine</li> <li>Endocrinology</li> <li>General Surgery</li> <li>Infectious Diseases</li> <li>Internal Medicine</li> <li>In-Vitro Fertilization (IVF)</li> <li>Laboratory Medicine</li> <li>Liver Transplant &amp; Hepatic Surgery</li> <li>Maxillofacial Surgery</li> <li>Medical Gastroenterology</li> <li>Medical Oncology &amp; Clinical Hematology</li> <li>Medical Oncology</li> <li>Minimally Invasive Gynecology</li> <li>Neonatology</li> <li>Nephrology</li> <li>Neuro Modulation</li> <li>Nutrition &amp; Dietetics</li> <li>Neurology</li> <li>Neurosurgery</li> <li>Obstetrics And Gynecology</li> <li>Ophthalmology</li> <li>Orthopedics &amp; Joint Replacement</li> <li>Pain Management</li> <li>Pediatric Surgery</li> <li>Physiotherapy</li> <li>Plastic Surgery</li> <li>Psychiatry</li> <li>Pulmonology</li> <li>Renal Transplant</li> <li>Reproductive Medicine &amp; IVF</li> <li>Rheumatology</li> <li>Robotic Surgery</li> <li>Surgical Gastroenterology</li> <li>Surgical Oncology</li> <li>Urology</li> <li>Vascular and endovascular surgery</li> </ul> <p style="text-align: justify;"> </p> <p style="text-align: justify;"><strong><span style="text-decoration: underline;">JOURNAL PARTICULARS</span></strong></p> <table> <tbody> <tr> <td width="281"> <p>Title</p> </td> <td width="517"> <p><strong>Innovative Journal of Medical Sciences</strong></p> </td> </tr> <tr> <td width="281"> <p>Frequency</p> </td> <td width="517"> <p>Quarterly</p> </td> </tr> <tr> <td width="281"> <p>E- ISSN</p> </td> <td width="517"> <p>2581-4346</p> </td> </tr> <tr> <td width="281"> <p>P-ISSN</p> </td> <td width="517"> <p>-</p> </td> </tr> <tr> <td width="281"> <p>DOI</p> </td> <td width="517"> <p><strong><a href=""></a></strong></p> </td> </tr> <tr> <td width="281"> <p>Publisher</p> </td> <td width="517"> <p><strong>Mr. Rahul Nahata</strong>, B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur-458001, Madhya Pradesh</p> </td> </tr> <tr> <td width="281"> <p>Chief Editor</p> </td> <td width="517"> <p>Dr. M.A. Naidu</p> </td> </tr> <tr> <td width="281"> <p>Starting Year</p> </td> <td width="517"> <p>2017</p> </td> </tr> <tr> <td width="281"> <p>Subject</p> </td> <td width="517"> <p>Computer Science and Engineering subjects</p> </td> </tr> <tr> <td width="281"> <p>Language</p> </td> <td width="517"> <p>English Language</p> </td> </tr> <tr> <td width="281"> <p>Publication Format</p> </td> <td width="517"> <p>Online</p> </td> </tr> <tr> <td width="281"> <p>Email Id</p> </td> <td width="517"> <p>,</p> </td> </tr> <tr> <td width="281"> <p>Mobile No.</p> </td> <td width="517"> <p>+91-7049737901</p> </td> </tr> <tr> <td width="281"> <p>Website</p> </td> <td width="517"> <p><a href="" aria-invalid="true"></a></p> </td> </tr> <tr> <td width="281"> <p>Address</p> </td> <td width="517"> <p>B.R. Nahata Smriti Sansthan, BRNSS PUBLICATION HUB, B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur-458001, Madhya Pradesh</p> </td> </tr> </tbody> </table> <p style="text-align: justify;"> </p> </div> en-US <p>This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.</p> (Prof. M A Naidu) (Dr. Nilesh Jain) Sat, 30 Jul 2022 06:41:19 +0000 OJS 60 Booster doses of COVID-19 vaccine: Rationales, implications and way forward for African countries <p>To contain a pandemic, access to an effective and safe vaccine is a global public health necessity. However, an effective and safe vaccine will not protect against a disease, unless it is given to susceptible persons in the proper dosage and in a timely manner. Since the commencement of the Coronavirus pandemic, every country has been attempting to develop or obtain a vaccine to safeguard their citizens. Because many developing countries, particularly those in Africa, lack the technological capacity to manufacture vaccines, their best option is to purchase one. As a result, many African countries have been able to obtain the initial dose of COVID-19 vaccines, but obtaining the booster doses has proven difficult for many. For multiple-dose vaccines, the interval between doses is crucial to reaping the full advantages of any specific vaccine. At the moment, public health officials are afraid that delay in receiving booster doses will allow the coronavirus to outsmart immunization efforts. While some argue that delaying booster doses will allow host immunity to wane, potentially leading to the emergence of a new, more contagious variant of concern (VOC) that may defeat the vaccine and grounds already conquered, others argue that up to 3 months between doses of two approved vaccines should be allowed instead of the one month studied in vaccine clinical trials. In ananxious attempt to stem the massive increase in confirmed cases and to prevent the spread of a new, more contagious variant of the virus, the highly developed and rich countries have continued to make concerted efforts to get as many people as possible vaccinated with multiple number of doses, without considering the poor COVID-19 vaccine supply chain or the fragile health systems of resource-limited countries like those in Africa. The purpose of this review is to look at the rationales for COVID-19 vaccine booster doses, supply chain bottlenecks, implications and recommendations for African countries.</p> Seyi Samson Enitan Copyright (c) 2022 Wed, 15 Jun 2022 00:00:00 +0000 Method development and validation of Favipiravir by RP-HPLC <p>Favipiravir (FVP) shows antiviral activity to tackle many viruses. It is very important for further analytical tests as a potential drug for COVID-19. A simple, accurate, precise, rapid, and gradient reverse phase high-performance liquid chromatography method developed for FVP pharmaceutical formulation. Analysis was carried out by Cosmosil C18 (250 mm × 4.6ID, Particle size: 5 micron). The mobile phase consisted of Methanol: Water (75:25, v/v). pH of Mobile Phase: 3 (pH is adjusted with o-phosphoric acid) The mobile phase was filtered and degassed through a 0.45 mm membrane filter before use and then pumped at a flow rate of 0.8 mL/min. The ultraviolet (UV) detection and column temperature were 227 nm, and 30°C. The retention time of FVP was found to be 4 min. The run time was 9 min under these chromatographic conditions. Linearity for FVP concentration 10–50 ppm has been observed with coefficient of determination of 0.9995. The recovery (%) was in the range of 98.94–99.12%, while the mean RSD (%) is 0.23%. The developed method was found to be sensitive (LOD and LOQ was found to be 0.2236 and 0.6776 resp.) Proposed method has been successfully applied for method development and validation of FVP in pharmaceutical formulations.</p> Dr. Amit Suryakant Tapkir Copyright (c) 2022 Wed, 15 Jun 2022 00:00:00 +0000 Identification of substance abuse among medical students in a Nigerian University <p>Objective: The aim of the study was to identify substance abuse among medical students of the College of Medicine, University of Lagos, Nigeria, and correlate it with their urine samples. Methods: A cross-sectional study was conducted among 150 undergraduate students of the College of Medicine University of Lagos, Nigeria. Ethical approval was obtained for the study and informed consent obtained from the participants before the commencement of the study. Data on the knowledge and prevalence of drug addiction were collected from the undergraduate students using a validated self-developed questionnaire while standard sample bottles were used to collect the students’ urine samples. Data collected were summarized using descriptive statistics. Chi-square was used to establish an association between the variables. Results: Sixty-three (42.2%) male and 87 (57.8%) female medical students participated in this study out of which 99 (65.9%) had good knowledge of drug addiction, 21 (15.6%) admitted that they have taken drugs not prescribed by a physician while 33(24.4%) claimed to have previously done drug test. The prevalence of drug abuse among the students was 15.6%. The age with the highest rate of drug abuse was 11–18 years. Tramadol was the most abused drug by the students while the most preferred route of drug abuse was oral route 20 (14.8%). Conclusion: There was a low prevalence of substance abuse among the medical students. BIOEASYTM immunoassay Multi-Drug Test Card was effective in screening the student’s urine. There is an urgent need for interventions like health education and training to be established in our higher institutions.</p> Okpalanma Nneoma Copyright (c) 2022 Wed, 15 Jun 2022 00:00:00 +0000 Development and estimation of carvedilol in oral dosage form using HPLC method <p>Introduction: Analytical chemistry is the study of the separation, identification, and quantification of the chemical components of natural and artificial materials. It deals with methods for determining the chemical composition of samples of matter. Materials and Methods: Chemicals and standards used as a material and methods to performing the task. Many trials were performed. Results: The present investigation reported in the thesis was aimed to develop a new method development and validation for the estimation of carvedilol by reversed-phase high-performance liquid chromatography (RP-HPLC) method. The literature reveals that there are no analytical methods reported for the estimation carvedilol by RP-HPLC method.&nbsp;</p> Tata Praveena Copyright (c) 2022 Tata Praveena Thu, 06 Oct 2022 00:00:00 +0000 Development and validation of a stability indicating RP-HPLC method for estimation of daclatasvir in pharmaceutical dosage form <p>Introduction: The aim of the present investigation is to develop and validate a novel, accurate, precise, and sensitive and stability indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method for the quantitative determination of daclatasvir in pure and pharmaceutical formulation. Materials and Methods: The method development was found to be having suitable applications for routine quality control analysis. Pharmaceutical analysis plays a key role in the Quality Assurance and Quality Control of bulk drugs. Analytical chemistry involves separating, identifying, and determining the relative amounts of components in a sample matrix. Pharmaceutical analysis is a specialized branch of analytical chemistry. Pharmaceutical analysis derives its principles from various branches of sciences such as physics, microbiology, nuclear science, and electronics. Qualitative analysis reveals the chemical identity of the sample. Results: To establish an optimized method, two trails were conducted with different compositions. Finally, the mobile phase selected for the analysis was composed of acetonitrile and 0.1% formic acid buffer adjusted to pH 4.5 in the ratio of 40: 60 v/v at flow rate of 1 mL/min. The maximum response was observed at 305 nm and was optimized for measuring the absorbance. The sharp peak of daclatasvir was retained at 4.34 min. Conclusion: By the obtained results and reports, the developed RP-HPLC method for the estimation of daclatasvir was found to be more efficient and accurate.</p> Manku Manikanta Copyright (c) 2022 Manku Manikanta Fri, 28 Oct 2022 00:00:00 +0000